Remove 2013 Remove Development Remove Management Remove Pharmaceuticals
article thumbnail

Strategic Choices Need to Be Made Simultaneously, Not Sequentially

Harvard Business Review

The CEO of a large Australian company called me to relay a particular strategy development problem his firm was facing, and ask for my advice. And Capabilities and Management Systems act as a reality check on the Where to Play and How to Win choice. Lafley, called Playing to Win.

article thumbnail

The First Step to Fixing U.S. Manufacturing

Harvard Business Review

A few outlier industries (notably pharmaceuticals, medical devices, and computers) prop up the sector’s aggregate performance; most others have experienced flat growth or outright declines in real GDP over the past two decades. In some instances, the end results were firm closures and lost jobs. manufacturers are taking notice.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The 3 Things CEOs Worry About the Most

Harvard Business Review

Please note that titles used here reflect the positions the individuals held in 2013, when we conducted the interviews for a separate article ). Talent Management. ” CEOs also worried about whether their high potential employees were being properly developed. One area that proved especially challenging was mobility.

CEO 8
article thumbnail

Health Care Becomes Entrepreneurial (Finally)

Harvard Business Review

While the managed care movement made a similar run in the early 1990s, the movement towards accountable care, bundled payments , and other population health efforts have not caused the type of backlash that managed care did ? billion in 2013, up 39% from 2012. These technologies currently affect a small share of the population.

article thumbnail

Leading in Complex Times

Harvard Business Review

I found myself reflecting on this recently while speaking with two business leaders in one of the world’s great pharmaceutical companies. How likely was it that they would be on top of the rapid developments in Asian consumer markets, or in technology and design emanating from Silicon Valley? Leadership Managing uncertainty'

article thumbnail

We Need More Transparency on the Cost of Specialty Drugs

Harvard Business Review

Take Sovaldi, launched by Gilead Sciences in late 2013 as a treatment for hepatitis C virus (HCV) infection and recently superseded by Gilead’s newest drug, Harvoni. To illustrate the problem, let’s start with an example from October 2013, when Express Scripts decided to exclude 46 drugs from its formulary. Even the U.S.

Cost 8
article thumbnail

We Need More Transparency on the Cost of Specialty Drugs

Harvard Business Review

Take Sovaldi, launched by Gilead Sciences in late 2013 as a treatment for hepatitis C virus (HCV) infection and recently superseded by Gilead’s newest drug, Harvoni. To illustrate the problem, let’s start with an example from October 2013, when Express Scripts decided to exclude 46 drugs from its formulary. Even the U.S.

Cost 8